Comparable pharmacokinetics of 85 mg RightSize nilotinib (XS003) and 150 mg Tasigna in healthy volunteers using a hybrid nanoparticle-based formulation platform for protein kinase inhibitors. This is ...

A multicenter phase II trial of gefitinib 500 mg/day in 193 patients with advanced epidermal growth factor receptor-positive solid tumors who had failed previous chemotherapy: Interim data ...

Unique solution enabling researchers to profile human oral drug bioavailability in vitro, in their own laboratories Expands access to CN Bio’s robust multi-organ Gut/Liver-on-a-chip model to ...

Boehringer Ingelheim has struck a deal to apply Nanoform's nanoparticle technology to its preclinical pipeline prospects. The master services agreement positions the partners to work to improve the ...

Many drugs are poorly water-soluble and lipophilic (fat-loving), and both pose challenges to bioavailability. As you’re probably aware, the human body, including the GI tract, is mostly water, so if a ...

The pharmaceutical industry is entering an inflection point driven by the recognition that highly potent cancer drugs are only as effective as their ability to reach tumors with sufficient ...